The World Health Organisation validated the Sinovac-CoronaVac COVID-19 vaccine for emergency use, giving countries, funders, procuring agencies, and communities the assurance that it meets international standards for safety, efficacy, and manufacturing, WHO press service announced in its statement.
According to WHO, the countries that have purchased a vaccine can be confident that it meets international standards of safety, efficiency, and production. Now the drug can be supplied as a part of the international initiative COVAX.
“The world desperately needs multiple COVID-19 vaccines to address the huge access inequity across the globe,” Dr. Mariângela Simão, WHO Assistant Director General for Access to Health Products, said. “We urge manufacturers to participate in the COVAX Facility, share their know-how and data and contribute to bringing the pandemic under control.”
The CoronaVac vaccine produced by the Chinese company Sinovac was registered by the Ministry of Health of Ukraine on March 10, 2021, and passed all the stages of clinical trials, officially confirming the efficiency and safety of the vaccine.
It is widely used to protect the population from the pandemic in China, Brazil, Mexico, Chile, Turkey, Indonesia, Thailand, Malaysia, and other countries.
The Sinovac-CoronaVac product is an inactivated vaccine. Its easy storage requirements make it very manageable and particularly suitable for low-resource settings.One of the main advantages of Sinovac vaccine is that it can be stored in a standard refrigerator at 2-8 degrees Celsius.
Currently, Ukraine has received 1.7 million doses of CoronaVac vaccine, a total of 1.9 million doses have been agreed.